Literature DB >> 14722279

Isolation of CD4-independent primary human immunodeficiency virus type 1 isolates that are syncytium inducing and acutely cytopathic for CD8+ lymphocytes.

Bouchra Zerhouni1, Julie A E Nelson, Kunal Saha.   

Abstract

Previous studies have established the existence of CD4-independent simian immunodeficiency virus, human immunodeficiency virus type 2 (HIV-2), and laboratory strains of HIV-1. However, whether CD4-independent viruses may also exist in HIV-1-infected patients has remained unclear. We have recently reported the isolation of viruses from an AIDS patient that were able to infect CD8(+) cells independent of CD4, using CD8 as a receptor. Using a similar approach, here we examined viruses from 12 randomly selected patients (obtained from the AIDS Research and Reference Program, National Institutes of Health) for the presence of CD4-independent HIV-1. CD4-independent variants were isolated from infected CD8(+) cells from the viral quasispecies of 7 of 12 patients. The CD4-independent isolates were able to infect primary CD8(+) cells as well as a CD4(-) CD8(+) T-cell line. Soluble CD4 and blocking anti-CD4 or -CD8 antibody had no effect on infection of CD8(+) cells. Remarkably, two of the seven CD4-independent isolates, but not their parental bulk viruses, induced syncytia and caused acute death of infected CD8(+) cells. Some of the CD4-independent variants were also able to infect U87 cells that were negative for CD4, CD8, and common HIV coreceptors, suggesting a novel entry mechanism for these isolates. The CD4-independent isolates were derived from adults and children infected with subtypes A, B, and D. Although no common motif for CD4 independence was found, novel sequence changes were observed in critical areas of the envelopes of the CD4-independent viruses. These results demonstrate that HIV-1-infected patients can frequently harbor viruses that are able to mediate CD4-independent infection of CD8(+) cells. In addition, this study also provides evidence of primary HIV-1 variants that are syncytium inducing and acutely cytopathic for CD8(+) lymphocytes.

Entities:  

Mesh:

Year:  2004        PMID: 14722279      PMCID: PMC321385          DOI: 10.1128/jvi.78.3.1243-1255.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Diversity of envelope glycoprotein from human immunodeficiency virus type 1 of recent seroconverters in Thailand.

Authors:  F E McCutchan; K Viputtigul; M S de Souza; J K Carr; L E Markowitz; P Buapunth; J G McNeil; M L Robb; S Nitayaphan; D L Birx; A E Brown
Journal:  AIDS Res Hum Retroviruses       Date:  2000-05-20       Impact factor: 2.205

2.  HIV type 1 variation in World Health Organization-sponsored vaccine evaluation sites: genetic screening, sequence analysis, and preliminary biological characterization of selected viral strains. WHO Network for HIV Isolation and Characterization.

Authors: 
Journal:  AIDS Res Hum Retroviruses       Date:  1994-11       Impact factor: 2.205

3.  Frequent infection of peripheral blood CD8-positive T-lymphocytes with HIV-1. Edinburgh Heterosexual Transmission Study Group.

Authors:  W J Livingstone; M Moore; D Innes; J E Bell; P Simmonds
Journal:  Lancet       Date:  1996-09-07       Impact factor: 79.321

4.  Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity.

Authors:  C C LaBranche; T L Hoffman; J Romano; B S Haggarty; T G Edwards; T J Matthews; R W Doms; J A Hoxie
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

5.  Patterns of changes in human immunodeficiency virus type 1 V3 sequence populations late in infection.

Authors:  J A Nelson; F Baribaud; T Edwards; R Swanstrom
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

6.  Human immunodeficiency virus Env-independent infection of human CD4(-) cells.

Authors:  S Pang; D Yu; D S An; G C Baldwin; Y Xie; B Poon; Y H Chow; N H Park; I S Chen
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

7.  Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization.

Authors:  C S Hung; N Vander Heyden; L Ratner
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

8.  Signature pattern analysis: a method for assessing viral sequence relatedness.

Authors:  B Korber; G Myers
Journal:  AIDS Res Hum Retroviruses       Date:  1992-09       Impact factor: 2.205

9.  CD8+ T lymphocytes in the lung of acquired immunodeficiency syndrome patients harbor human immunodeficiency virus type 1.

Authors:  G Semenzato; C Agostini; L Ometto; R Zambello; L Trentin; L Chieco-Bianchi; A De Rossi
Journal:  Blood       Date:  1995-05-01       Impact factor: 22.113

10.  Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization.

Authors:  F De Wolf; E Hogervorst; J Goudsmit; E M Fenyö; H Rübsamen-Waigmann; H Holmes; B Galvao-Castro; E Karita; C Wasi; S D Sempala
Journal:  AIDS Res Hum Retroviruses       Date:  1994-11       Impact factor: 2.205

View more
  24 in total

Review 1.  HIV and the chemokine system: 10 years later.

Authors:  Paolo Lusso
Journal:  EMBO J       Date:  2006-01-26       Impact factor: 11.598

2.  Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors.

Authors:  Zhufang Li; Nannan Zhou; Yongnian Sun; Neelanjana Ray; Max Lataillade; George J Hanna; Mark Krystal
Journal:  Antimicrob Agents Chemother       Date:  2013-06-17       Impact factor: 5.191

3.  Down-modulation of CD8αβ is a fundamental activity of primate lentiviral Nef proteins.

Authors:  Anke Heigele; Michael Schindler; Clement W Gnanadurai; Jolie A Leonard; Kathleen L Collins; Frank Kirchhoff
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

4.  "Cytoplasmic domain effects on exposure of co-receptor-binding sites of HIV-1 Env".

Authors:  Andrei N Vzorov; Richard W Compans
Journal:  Arch Virol       Date:  2016-08-03       Impact factor: 2.574

5.  HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug.

Authors:  Susan M Schader; Susan P Colby-Germinario; Peter K Quashie; Maureen Oliveira; Ruxandra-Ilinca Ibanescu; Daniela Moisi; Thibault Mespléde; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

Review 6.  Candidate antibody-based therapeutics against HIV-1.

Authors:  Rui Gong; Weizao Chen; Dimiter S Dimitrov
Journal:  BioDrugs       Date:  2012-06-01       Impact factor: 5.807

7.  A single amino acid change and truncated TM are sufficient for simian immunodeficiency virus to enter cells using CCR5 in a CD4-independent pathway.

Authors:  A Bonavia; B T Bullock; K M Gisselman; B J Margulies; J E Clements
Journal:  Virology       Date:  2005-10-10       Impact factor: 3.616

8.  High levels of human immunodeficiency virus infection of CD8 lymphocytes expressing CD4 in vivo.

Authors:  Alexandra Cochrane; Stuart Imlach; Clifford Leen; Gordon Scott; Dermot Kennedy; Peter Simmonds
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

9.  Matrix and envelope coevolution revealed in a patient monitored since primary infection with human immunodeficiency virus type 1.

Authors:  Elodie Beaumont; Daniela Vendrame; Bernard Verrier; Emmanuelle Roch; François Biron; Françis Barin; Fabrizio Mammano; Denys Brand
Journal:  J Virol       Date:  2009-07-22       Impact factor: 5.103

10.  Binding mode characterization of NBD series CD4-mimetic HIV-1 entry inhibitors by X-ray structure and resistance study.

Authors:  Francesca Curreli; Young Do Kwon; Hongtao Zhang; Yongping Yang; Daniel Scacalossi; Peter D Kwong; Asim K Debnath
Journal:  Antimicrob Agents Chemother       Date:  2014-07-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.